Litigation Details for Mayo Clinic v. Celgene Corporation (N.D. Cal. 2023)
✉ Email this page to a colleague
Mayo Clinic v. Celgene Corporation (N.D. Cal. 2023)
| Docket | ⤷ Start Trial | Date Filed | 2023-10-06 |
| Court | District Court, N.D. California | Date Terminated | 2023-11-09 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Vince Girdhari Chhabria |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,045,501; 6,315,720; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,141,018; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,492,406; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622; 9,155,730; 9,393,238 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Mayo Clinic v. Celgene Corporation
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for Mayo Clinic v. Celgene Corporation (N.D. Cal. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-10-06 | External link to document | |||
| 2023-10-06 | 1 | Complaint | , distribution: Patent Nos. 6,045,501 (the “’501 Patent”); 6,561,976 (the “’976 Patent”); 20 6,908,432… REMS ’501 6,045,501 28-Aug-98 4-Apr-00 28-Aug-18 Methods… ’517 Patent, ’720 Patent, ’977 Patent, ’784 Patent, ’740 Patent, ’800 Patent, 4 ’217 Patent, ’569 …569 Patent, ’886 Patent, ’717 Patent, ’498 Patent, ’531 Patent, ’095 Patent, ’120 5 Patent, ’621 Patent…infringe the ’800 Patent, ’217 Patent, ’569 Patent, ’498 Patent, ’095 Patent, ’621 Patent, 22 23 24 195 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
